Literature DB >> 15975027

Amyloid associated proteins in Alzheimer's and prion disease.

R Veerhuis1, R S Boshuizen, A Familian.   

Abstract

Clustering of activated microglia in Abeta deposits is related to accumulation of amyloid associated factors and precedes the neurodegenerative changes in AD. Microglia-derived pro-inflammatory cytokines are suggested to be the driving force in AD pathology. Inflammation-related proteins, including complement factors, acute-phase proteins, pro-inflammatory cytokines, that normally are locally produced at low levels, are increasingly synthesized in Alzheimer's disease (AD) brain. Similar to AD, in prion diseases (Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease and experimentally scrapie infected mouse brain) amyloid associated factors and activated glial cells accumulate in amyloid deposits of conformational changed prion protein (PrPres). Biological properties of Abeta and prion (PrP) peptides, including their potential to activate microglia, relate to Abeta and PrP peptide fibrillogenic abilities that are influenced by certain amyloid associated factors. However, since small oligomers of amyloid forming peptides are more toxic to neurons than large fibrils, certain amyloid associated factors that enhance fibril formation, may sequester the potentially harmful Abeta and PrP peptides from the neuronal microenvironment. In this review the positive and negative actions of amyloid associated factors on amyloid peptide fibril formation and on the fibrillation state related activation of microglia will be discussed. Insight in these mechanisms will enable the design of specific therapies to prevent neurodegenerative diseases in which amyloid accumulation and glial activation are prominent early features.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975027     DOI: 10.2174/1568007054038184

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  17 in total

1.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

Review 2.  Nanoimaging for protein misfolding and related diseases.

Authors:  Yuri L Lyubchenko; Simon Sherman; Luda S Shlyakhtenko; Vladimir N Uversky
Journal:  J Cell Biochem       Date:  2006-09-01       Impact factor: 4.429

3.  Amyloid formation in denatured single-mutant lysozymes where residual structures are modulated.

Authors:  Tomonori Mishima; Takatoshi Ohkuri; Akira Monji; Taiji Imoto; Tadashi Ueda
Journal:  Protein Sci       Date:  2006-09-08       Impact factor: 6.725

4.  Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.

Authors:  Joao P Lopes; Catarina R Oliveira; Paula Agostinho
Journal:  Cell Mol Neurobiol       Date:  2007-10-27       Impact factor: 5.046

5.  Critical Influence of Cosolutes and Surfaces on the Assembly of Serpin-Derived Amyloid Fibrils.

Authors:  Michael W Risør; Dennis W Juhl; Morten Bjerring; Joachim Mathiesen; Jan J Enghild; Niels C Nielsen; Daniel E Otzen
Journal:  Biophys J       Date:  2017-08-08       Impact factor: 4.033

Review 6.  The significance of neuroinflammation in understanding Alzheimer's disease.

Authors:  P Eikelenboom; R Veerhuis; W Scheper; A J M Rozemuller; W A van Gool; J J M Hoozemans
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

Review 7.  Complement in the brain.

Authors:  Robert Veerhuis; Henrietta M Nielsen; Andrea J Tenner
Journal:  Mol Immunol       Date:  2011-05-04       Impact factor: 4.407

8.  Search for amyloid-binding proteins by affinity chromatography.

Authors:  Miguel Calero; Agueda Rostagno; Jorge Ghiso
Journal:  Methods Mol Biol       Date:  2012

Review 9.  Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease.

Authors:  Milan Fiala; Robert Veerhuis
Journal:  Exp Gerontol       Date:  2009-08-21       Impact factor: 4.032

10.  Ah receptor represses acute-phase response gene expression without binding to its cognate response element.

Authors:  Rushang D Patel; Iain A Murray; Colin A Flaveny; Ann Kusnadi; Gary H Perdew
Journal:  Lab Invest       Date:  2009-03-30       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.